Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer
- PMID: 12787717
- DOI: 10.1016/s0305-7372(03)00098-7
Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer
Comment on
-
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.Cancer. 2002 Jul 15;95(2):361-76. doi: 10.1002/cncr.10647. Cancer. 2002. PMID: 12124837
Publication types
LinkOut - more resources
Full Text Sources